May 23, 2014
Authored and Edited by Linda J. Thayer
One advantage of the AIA’s new post-grant proceedings over litigating patent validity in federal district court is that the USPTO currently gives claims in unexpired patents their broadest reasonable interpretation (BRI) in light of the specification, which frequently means that more potentially invalidating prior art may be used. The Office justifies the use of BRI for unexpired patents because, consistent with examination, the patent owner has an ability to amend claims. Office Patent Trial Practice Guide, 77 Fed. Reg. 48,756, 48,764 (Aug. 14, 2012).
When a patent has expired, however, the PTO has acknowledged that use of BRI is no longer appropriate and the patent should be examined under the claim construction espoused in Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (en banc), which is the standard applied by district courts. According to Phillips, the terms of a claim should generally be given their “ordinary and customary meaning” which is the “meaning that a term would have to one of ordinary skill in the art in question at the time of the invention.” Id.at 1312.
Should patent owners be allowed to take actions in the middle of an IPR proceeding that would change the standard applied by the Board? In Amkor Technology, Inc. v. Tessera, Inc., IPR201-00242, pending since April 9, 2013, the matters were fully briefed, discovery had concluded, and the Oral argument was scheduled for May 21, 2014 (Paper 91). On April 11, 2014, Tessera filed a terminal disclaimer disclaiming the remainder of the patent term and, on April 14, 2014, asked the Board to apply the Phillips standard, instead of BRI (See Paper 119). According to the Patent Owner, when the claims are given their “ordinary and customary meaning,” Amkor has not presented a prima facie case of unpatentability and the IPR should be terminated. Tessera argued that the filing of the terminal disclaimer immediately terminated its ability to amend it claims and therefore changed the standard under which the claims should be examined.
In response, Petitioner Amkor disagreed, noting that the terminal disclaimer does not take effect until the Office issues an IPR certificate. Moreover, Tessera itself applied BRI in its responses to Amkor’s unpatentability arguments and the Board should not allow the standard to shift at this point to discourage other patent owners from engaging is such a tactic.
On May 22, 2014, the Board issued its decision, concluding that the terminal disclaimer should be held in abeyance until the IPR terminates or a final written decision is issued, and that the claims should continue to be given their broadest reasonable interpretation. (Paper 129, p. 2). The Board exercised its exclusive jurisdiction pursuant to 37 C.F.R. § 42.7(b) to “vacate or hold in abeyance any non-Board action directed to a proceeding while a[] … patent is under the jurisdiction of the Board unless the action was authorized by the Board.” Id., p. 6. The Board agreed with Petitioner that allowing Patent Owner to change the standard at the last minute would “defeat the purpose of inter partes review to provide a timely, cost-effective determination on patentability” and would encourage gamesmanship. Id., p. 8. The Board noted that the Preliminary Response was Patent Owner’s opportunity to argue how the claims were to be interpreted and that any arguments not raised and fully briefed by Patent Owner were waived. Id., p. 9.
In view of this decision, Patent Owners responding to an IPR petition should determine if any involved patent will expire during the course of or shortly after projected conclusion of the IPR. If so, the Patent Owner should consider whether filing a terminal disclaimer would improve its probability of success against the petitioner’s claims of unpatentability and outweigh any effects the shortened term may have on the litigation strategy. If so, the terminal disclaimer should be filed before or with the Patent Owner’s Preliminary Response.
Copyright © 2014 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information.
June 10-12, 2024
San Francisco
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
10th Annual Georgia Asian Pacific American Bar Association Gala
May 29, 2024
Atlanta
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.